Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

Communication During Hospitalization About Resuscitation Trial

NCT02984124 · View on ClinicalTrials.gov ↗

Study Summary

This multicenter RCT of 200 hospitalized patients and their family members evaluates an "informed assent" approach to discussing cardiopulmonary resuscitation, compared to usual care, in older seriously ill hospitalized patients with severe life-limiting illness or severe functional impairment.

Interventions

  • BEHAVIORAL Informed Assent Discussion
  • BEHAVIORAL Usual Care with Attention Control

Study Locations (4)

North Carolina

  • University of North Carolina — Chapel Hill

South Carolina

  • Medical University of South Carolina — Charleston

Vermont

  • University of Vermont — Burlington

Washington

  • University of Washington — Seattle

Trial Details

FieldValue
Enrollment Target 182 participants
Start Date 2016-12
Est. Completion 2025-12
Phase Phase 2

Sponsor

University of Vermont

107 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02984124

The ClinicalTrials.gov registry entry for NCT02984124 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 107 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 6 conditions, with End Stage Renal Disease appearing as the primary indexed condition, and to 2 interventions — of which Informed Assent Discussion is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02984124 reports 4 study locations spanning 4 distinct geographic areas — top geographies include North Carolina, South Carolina, Vermont. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02984124 about?

NCT02984124 is a clinical study titled "Communication During Hospitalization About Resuscitation Trial". This multicenter RCT of 200 hospitalized patients and their family members evaluates an "informed assent" approach to discussing cardiopulmonary resuscitation, compared to usual care, in older seriously ill hospitalized patients with severe life-limiting illness or severe functional impairment.

What is the current status of trial NCT02984124?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 182 participants. The study started on 2016-12. Estimated completion is 2025-12.

What conditions does trial NCT02984124 study?

This clinical trial studies the following conditions: End Stage Renal Disease, Severe Life-limiting COPD, Severe Life-limiting Heart Failure, Severe Life-limiting Cirrhosis, Severe Life-limiting Malignancy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02984124?

The interventions under investigation include: Informed Assent Discussion (BEHAVIORAL), Usual Care with Attention Control (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02984124?

This trial is sponsored by University of Vermont, which has 107 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02984124 being conducted?

This trial has 4 study locations across North Carolina, South Carolina, Vermont, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial